These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 21864263

  • 21. The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.
    Tarnowski M, Paradowska-Gorycka A, Dąbrowska-Zamojcin E, Czerewaty M, Słuczanowska-Głąbowska S, Pawlik A.
    Expert Opin Drug Metab Toxicol; 2016; 12(1):41-55. PubMed ID: 26609565
    [Abstract] [Full Text] [Related]

  • 22. Biological response modifiers in the management of rheumatoid arthritis.
    Louie SG, Park B, Yoon H.
    Am J Health Syst Pharm; 2003 Feb 15; 60(4):346-55. PubMed ID: 12625216
    [Abstract] [Full Text] [Related]

  • 23. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part I. Tumor necrosis factor alpha inhibitors].
    Swierkot J, Madej M.
    Pol Merkur Lekarski; 2011 Apr 15; 30(178):283-8. PubMed ID: 21595176
    [Abstract] [Full Text] [Related]

  • 24. Anti-TNF in rheumatoid arthritis: an overview.
    Radner H, Aletaha D.
    Wien Med Wochenschr; 2015 Jan 15; 165(1-2):3-9. PubMed ID: 25651945
    [Abstract] [Full Text] [Related]

  • 25. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ, Hyrich KL.
    BioDrugs; 2009 Jan 15; 23(2):111-24. PubMed ID: 19489652
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis.
    Tanaka Y.
    Curr Opin Rheumatol; 2012 May 15; 24(3):319-26. PubMed ID: 22388646
    [Abstract] [Full Text] [Related]

  • 29. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S, Tolusso B, Petricca L, Bui L, Di Sante G, Peluso G, Benvenuto R, Fedele AL, Federico F, Ferraccioli G, Gremese E.
    Ann Rheum Dis; 2017 Jul 15; 76(7):1228-1236. PubMed ID: 28119289
    [Abstract] [Full Text] [Related]

  • 30. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
    Park HJ, Ranganathan P.
    Discov Med; 2012 Mar 15; 13(70):229-34. PubMed ID: 22463799
    [Abstract] [Full Text] [Related]

  • 31. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL, Valesini G.
    BioDrugs; 2014 Apr 15; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [Abstract] [Full Text] [Related]

  • 32. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun 15; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 33. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis.
    Fleischmann RM, Iqbal I, Stern RL.
    Expert Opin Drug Saf; 2004 Sep 15; 3(5):391-403. PubMed ID: 15335295
    [Abstract] [Full Text] [Related]

  • 34. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H, Horiuchi T, Tsukamoto H, Ueda N.
    Cytokine; 2018 Jan 15; 101():56-63. PubMed ID: 27567553
    [Abstract] [Full Text] [Related]

  • 35. Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis.
    Xie X, Li F, Li S, Tian J, Chen JW, Du JF, Mao N, Chen J.
    Clin Rheumatol; 2018 Jan 15; 37(1):13-23. PubMed ID: 28600618
    [Abstract] [Full Text] [Related]

  • 36. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis.
    Murdaca G, Spanò F, Puppo F.
    Expert Opin Drug Saf; 2013 Nov 15; 12(6):801-4. PubMed ID: 23889669
    [Abstract] [Full Text] [Related]

  • 37. Plasmapheresis therapy in combination with TNF-α inhibitor and DMARDs: A multitarget method for the treatment of rheumatoid arthritis.
    Cheng Y, Yang F, Huang C, Huang J, Wang Q, Chen Y, Du Y, Zhao L, Gao M, Wang F.
    Mod Rheumatol; 2017 Jul 15; 27(4):576-581. PubMed ID: 27830969
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis.
    Venkateshan SP, Sidhu S, Malhotra S, Pandhi P.
    Pharmacology; 2009 Jul 15; 83(1):1-9. PubMed ID: 18957873
    [Abstract] [Full Text] [Related]

  • 39. Factors Predicting 2 Years of Remission and Low Disease Activity in Rheumatoid Arthritis Patients Treated with TNF-inhibitors.
    Conigliaro P, Triggianese P, Chimenti MS, Tonelli M, Sunzini F, Kroegler B, Perricone R.
    Isr Med Assoc J; 2017 Aug 15; 19(8):467-472. PubMed ID: 28825763
    [Abstract] [Full Text] [Related]

  • 40. Rheumatoid Arthritis - Anti-TNF.
    Chaabo K, Kirkham B.
    Int Immunopharmacol; 2015 Aug 15; 27(2):180-4. PubMed ID: 25962818
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.